Volume Spike Investor

Cell Therapeutics, Inc. (NASDAQ: CTIC) is trading up after it disclosed data from the pivotal phase III EXTEND clinical trial of pixantrone in relapsed or refractory, aggressive non-Hodgkin’s lymphoma patients who have failed 2 or more prior therapies. The company noted that updated analysis with additional follow-up data  were conducted and support the initial clinical trial results. Subgroup analysis demonstrated that pixantrone consistently improved PFS across subgroups compared with other chemotherapy agents.  At 8:27 AM EST we have seen 375,000 shares trade hands and the stock is up almost 6% at $1.25.  Average volume is now 17 million shares and the 52-week trading range is $0.05 to $2.23.

Jon C. Ogg